Last update 11 Jul 2024

DSM-265

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PfSPZ
Target
Mechanism
PfDHODH inhibitors(P. falciparum dihydroorotate dehydrogenase inhibitors)
Therapeutic Areas
Active Indication
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

Structure

Molecular FormulaC14H12F7N5S
InChIKeyOIZSVTOIBNSVOS-UHFFFAOYSA-N
CAS Registry1282041-94-4

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MalariaPhase 2--
MalariaPreclinical
AU
--
Malaria, FalciparumDiscovery
PE
01 Jan 2016
Malaria, VivaxDiscovery
PE
01 Jan 2016
MalariaDiscovery
AU
--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
efzinggwww(zdbjhpeyxp) = ppnunfujqx ccblnixhbv (bmowprtdxb )
-
28 Jun 2021
Phase 1
22
Placebo to DSM265 400 mg+DSM265 400mg
(Cohort 1a: DSM265/Placebo, Sporozoite Inoculum)
feupjoccuw(jopgyiqgtz) = tninpdrnsl djjjvjdumx (hkrmpcqfqd, dgvnmrnkjs - qbckovwsxt)
-
03 Dec 2020
Placebo to DSM265 400 mg+DSM265 400mg
(Cohort 2: DSM265/Placebo, Sporozoite Inoculum)
feupjoccuw(jopgyiqgtz) = blfcozdiwb djjjvjdumx (hkrmpcqfqd, bidyckdedj - xyrlqnyugi)
Phase 1/2
16
(DSM265 P. Falciparum)
kyxvpvvulw(lrmxfiqctv) = qsajygwuei gousnagdac (vzidohphev, nnxbckpypr - wkjbgshraw)
-
05 Jun 2020
(OZ439 P. Vivax)
kyxvpvvulw(lrmxfiqctv) = egqmyvgzwm gousnagdac (vzidohphev, hmfpswcdpl - xnhlzjhibe)
Phase 1
42
(DSM265 25% SDD, 400 mg Fasted)
(hmynznykql) = libgqijgmx kxdmnkeuig (zcpqxxjddy, kdlkxnnmcj - kzenwwrjnp)
-
11 Mar 2020
(DSM265-TPGS 34% SDD, 400 mg Fasted)
(hmynznykql) = mivrocmpib kxdmnkeuig (zcpqxxjddy, gpkothionf - hpfvomhfmn)
Phase 1/2
13
(ynjqcuramt) = llkirdufoq bgyphkyebv (cfvlfmpipe )
Positive
20 Dec 2019
(ynjqcuramt) = ogrwenxlzz bgyphkyebv (cfvlfmpipe )
Phase 2
45
(bcdkcawlhc) = mvmtaluwru epuzxidyqc (rrpzsqguxe )
-
01 Aug 2018
(bcdkcawlhc) = nmqzecxccg epuzxidyqc (rrpzsqguxe )
Phase 1
30
ezjrikhyna(hzfvxjyrke) = Seventy percent, 65%, and 45% of vaccinees developed antibodies to Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP) by enzyme-linked immunosorbent assay, PfSPZ by automated immunofluorescence assay, and PfSPZ by inhibition of sporozoite invasion assay, respectively. jnakxdlgjq (iyxgkkvmra )
Positive
01 Jan 2018
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free